7,8—二甲基—10—（D—1—核糖醇基）—异咯嗪半合成中间体气相色谱分析

提出以三氟乙酸酐作为衍生化试剂,将核黄素半合成中间体Ｎ－（Ｄ）－脱氧核糖醇基－３,４－二甲苯胺（Ⅰ）及４,５－二甲基－Ｎ－（Ｄ）－脱氧核糖醇基－２－偶氮苯基苯胺（Ⅱ）转化为低沸点易汽化物质,采用以苯乙酮作为内标,测定中间体（Ⅰ）和（Ⅱ）纯度的气相色谱法。方法具有分析速度快、准确度高、重现性好等优点,方法回收率（Ⅰ）为９６．９％￣１０１．２％、（Ⅱ）为９９．４％￣１００．４％,相对标准偏差（Ⅰ）在４     

固体酸催化二氟二苯甲酮和苯胺缩合合成N-(双(4-氟苯基)亚甲基)苯胺

以固体酸为催化剂,4,4’-二氟二苯甲酮与苯胺脱水缩合,合成了N-(双(4-氟苯基)亚甲基)苯胺.比较了不同固体酸催化剂H型ZSM-5、Na型ZSM-5、介孔分子筛MCM-41(Al)及强酸型离子交换树脂Amberlyst 15的催化效果.使用比表面、NH3-TPD对催化剂进行了表征,并与催化效果关联.考察了催化剂用量、原料摩尔比、浓度及溶剂等反应条件对产物收率的影响.产物通过熔点、核磁共振谱进行了表征.结果表明,HZSM-5固体酸催化剂具有优异的催化作用.在优化条件下,以对二甲苯为反应溶剂和脱水剂,4,4’-二氟二苯甲酮0.1 mol,苯胺0.2 mol,催化剂用量2.0 g,反应24 h,产物收率达91%.此外,催化剂易于分离,能够重复使用多次.     

2-(4-甲基苯基)-3-(N-乙酰基)-5-(2-羟基苯基)-1,3,4-噁唑啉的合成及与人血清白蛋白的相互作用

合成了2-(4-甲基苯基)-3-(N-乙酰基)-5-(2-羟基苯基)-1,3,4-噁唑啉(MPAHO),并用核磁共振波谱法和红外光谱法对其进行了表征。采用荧光光谱技术研究了MPAHO与人血清白蛋白(HSA)的相互作用。结果表明:MPAHO对HSA有较强的荧光猝灭作用,根据Stern-Volmer方程得到的荧光猝灭常数,可判断由于与MPAHO反应而导致HSA的荧光猝灭均属于静态猝灭。采用位点结合模型公式和Frster非辐射能量转移理论计算了结合常数、结合位点数、结合距离。从计算得到的热力学参数焓变ΔH和熵变ΔS,推断MPAHO与HSA之间的作用力为静电引力。并应用同步荧光光谱和三维荧光技术研究了MPAHO对HSA构象的影响。     

5-烃基-2,3-二甲基吡嗪N-单氧化物的合成

一烃基或二烃基吡嗪的N-单氧化物可以进行氯化、乙酰氧基化等反应,它是重要的有机合成中间体.据报道二烃基吡嗪与30％过氧化氢在醋酸中进行N-氧化反应,当二烃基吡嗪:30％过氧化氢:醋酸的摩尔比为1:2:5、反应温度70～80℃、反应时间8h时,产物是N-单氧化物;当摩尔比为1:4:10、反应温度95℃、反应时间8～24h时,产物是N-二氧     

1-(4-安替比林偶氮)-2-羟基-4-二甲苯胺的合成及其与铜(Ⅱ)显色反应的研究

合成了新显色剂1-(4-安替比林偶氮)-2-羟基-4-二甲苯胺(APHMA),并研究了其与Cu(Ⅱ)的显色反应。在pH 4.0的HAc-NaAc缓冲介质中,APHMA与Cu(Ⅱ)生成2∶1稳定络合物,最大吸收波长为560 nm,摩尔吸光系数为2.36×104L.mol-1.cm-1,Cu量在0~1.0μg/mL内符合比耳定律。已用于食品中铜的分析。     

新试剂5-(对-苯胺偶氮)-2,3-二氢-1,4-酞嗪二酮的电化学发光研究

应用自制的ECL-1型电致化学发光仪,对新试剂5-(对-苯胺偶氮)-2,3-二氢-1,4-酞嗪二酮(简称ADPD)在Na_2CO_3-NaHCO_3-H_3BO_3缓冲介质中的电化学发光行为作了研究。结果表明,当介质pH值为10.20时,在各种选定的实验条件下,施加+2.0V(vs.SCE)三角波脉冲电压,体系发光强度与ADPD浓度在2×10~(-9)～1×10~(-7)mol/L范围内呈线性关系。反应的检测限为5×10~(-10)mol/L。并且提出了ADPD电化学发光的可能机理。     

3-(N-取代苯基-2-乙酰胺基)硫基-4-N-取代邻羟苯基亚胺基-5-甲基-1,2,4-三唑类化合物的合成及生物活性研究

以对称二氨基硫脲为原料,与冰醋酸反应生成5-甲基-4-氨基-1,2,4-三唑-3-硫酮(1);在弱酸性条件下,1与取代水杨醛反应生成席夫碱中间体5-甲基-4-(N-取代邻羟苯基)亚胺基-1,2,4-三唑-3-硫酮(2a～2c);最后在碱性条件下分别与N-取代苯基-2-氯乙酰胺发生烷基化反应生成15种未见报道的目标化合物3-(N-取代苯基-2-乙酰胺基)硫基-4-(N-取代邻羟苯基)亚胺基-5-甲基-1,2,4-三唑(3a～3o),其结构经IR,1H NMR,13C NMR确证.初步生物测试表明,质量分数为0.01%时,3a～3o对白色念珠菌的抑菌率均达90%以上,具有很强的抑菌活性;对金黄色葡萄球菌、大肠杆菌的抑菌率达80%以上,具有较强的抑菌活性.     

2-(5-甲基-2-苯基-4-噁唑基)乙醇的合成工艺改进

以L-天门冬氨酸为原料,经过β-甲酯化,苯甲酰化,Dak in-W est反应,环合和氢化铝锂还原等反应步骤,以36.1%的总收率得到抗糖尿病药物的重要中间体2-(5-甲基-2-苯基-4-噁唑基)乙醇.用浓硫酸取代三氯氧磷作为关环剂,简化了环合工艺和后处理操作.     

2-(5-甲基-2-苯基-噁唑基)乙醇的合成

2-(5-甲基-2-苯基-噁唑基)乙醇的合成;Dakin-West反应;还原     

3,5-二(4-甲基苯基)吡啶的Suzuki偶联合成及其光学性能

以3,5-二溴吡啶和对甲基苯硼酸为原料,醋酸钯为催化剂,经Suzuki偶联反应合成了3,5-二(4-甲基苯基)吡啶(1),收率73%,其结构和性能经¹H NMR, ¹³C NMR, IR, 元素分析, UV-Vis, FL和X-射线单晶衍射表征。结果表明：1（CCDC: 1509844）属正交晶系,空间群P2₁2₁2₁,晶胞参数a=6.447 8(12) , b=7.240 2(14) , c=29.890 0(6) ,β=90°。1为非平面刚性共轭分子,荧光量子产率13.9%。     

1-[6-(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪-3-基]酰肼及其衍生物的合成与表征

以水合肼和硝酸胍为原料,经肼化、环化、氧化和肼化四步反应合成了1-[6-(3,5-二甲基-1H吡唑-1-基)-1,2,4,5-四嗪-3-基]酰肼(4);4与酰氯或磺酰氯反应合成了一系列新型的1-[6-(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪-3基]酰肼衍生物(6a～6j),其结构经1H NMR,IR...     

(4R-cis)-6-[2-[2-(4-氟苯基)-5-(1-异丙基)-3-苯基-4-[苯胺(羰基)]-1 H-吡咯-1-基]乙基]-2,2-二甲基-1,3-二氧己环-4-乙酸叔丁酯的波谱学研究

对(4R-cis)-6-[2-[2-(4-氟苯基)-5-(1-异丙基)-3-苯基-4-[苯胺(羰基)]-^1H-吡咯-1-基]乙基]-2,2-二甲基-1,3-二氧己环-4-乙酸叔丁酯的傅里叶变换离子回旋共振质谱(FT-ICR-MS)、核磁共振氢谱(^1H-NMR)、碳谱(^13C-NMR)以及^1H同核位移相关谱(^1H-^1HCOSY)、检出^1H的异核多量子相干谱(HMQC)和^1H检测的异核多键相关谱(HMBC)报道并进行解析。确定了^1H谱、^13C谱中各谱峰的归属,研究了其六元环部分的立体构象,并就空间效应对其化学位移的影响做了初步的探讨。     

2,2-二甲基-1-[5-二茂铁基-3-(三氟甲基)-1H-吡唑-1-基]丙-1-酮的合成及其电化学性质

以乙酰基二茂铁为原料,经3步反应合成了一个新型的二茂铁衍生物——2,2-二甲基-1-[5-二茂铁基-3-(三氟甲基)-1H-吡唑-1-基]丙-1-酮(4),其结构经1H NMR,ESI-MS,元素分析和X-射线单晶衍射表征。4属单斜晶系,P2(1)/c空间群,晶胞参数a=7.805 6(4),b=20.906 1(11),c=11.124 6(6),β=93.820(2)°,V=1 811.33(17)3,Z=4,Dc=1.482 g·cm-3,μ=0.872 mm-1,R1=0.034 8,wR2=0.089 2。采用循环伏安法研究了4的电化学性质。结果表明:4有一对可逆的氧化还原峰,Epa=0.640 V,Epc=0.482 V,ΔE=153 m V。     

Synthesis and Crystal Structure of Trans-4-[(5-(2,4-Dichlorophenoxy)-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyleneamino]-1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-one

The title compound trans-4-[(5-(2,4-dichlorophenoxy)-3-methyl-1-phenyl-1H-pyra-zol-4-yl)methyleneamino]-1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-one 3 (C28H23Cl2N5O2, Mr = 532.41) has been synthesized and its crystal structure was determined by single-crystal X-ray diffraction analysis. It crystallizes in triclinic, space group P1 with a = 8.9438(4), b = 11.6065(5), c = 14.2215(6) , α = 112.566(1), β = 92.324(2), γ = 102.91(1)o, V = 1315.65(10) 3, Z = 2, Dc = 1.344 g/cm3, μ(MoKα) = 0.282 mm-1, λ = 0.71073 , F(000) = 552, the final R = 0.0587 and wR = 0.1578 for 5071 observed reflections (I > 2σ(I)). X-ray analysis reveals that the product is a thermodynamically stable trans isomer. Intra-and intermolecular C(12)-H(12)···O(1) and C(28)-H(28)···O(1)#1 hydrogen bonds were observed in the title compound.     

1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼的合成工艺改进

以3,5-二甲基苯胺和2-莰酮为起始原料,在微波促进下,经缩合反应制得N-(3,5-二甲基苯基)-1-(1S,4S)-1,7,7-三甲基二环[2.2.1]庚烷-2-亚胺(1);1经硼氢化钠还原后再与羟胺-O-磺酸经胺化反应合成了1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼,总收率70.4%,其结构经1H NMR和ESI-MS确证。     

Synthesis of 5-Hydroxymethyl-8-methyl-3-(3-aryl-[1,2,4]oxadiazol-5-yl)-2H-pyrano[2,3-c]pyridin-2-ones and Their Esters

New 5-hydroxymethyl-8-methyl-3-(3-aryl-[1,2,4]oxadiazol-5-yl)-2H-pyrano-[2,3-c]pyridin-2-ones and their esters were synthesized. The structure of obtained compounds was determined through a complete ¹H NMR analysis.     

1-(2-Quinoxalyl)-, 1-[3,5-Di(trifluoromethyl)phenyl]-, 1-(2-Carboxyphenyl)-, and 1-Ethoxycarbonyl-4-oxo-4,5,6,7-tetrahydroindazoles

The corresponding 1-(2-quinoxalyl)-, 1-[3,5-di(trifluoromethyl)phenyl]-, and 1-ethoxycarbonyl-3-methyl-4-oxo-4,5,6,7-tetrahydroindazoles have been obtained from reactions of 2-acetyl-1,3-cyclohexanedione, its 5,5-dimethyl and 5-(2-furyl) derivatives, with 2-hydrazinoquinoxaline, 3,5-di(trifluoromethyl)phenylhydrazine, and ethoxycarbonylhydrazine. On interaction with ethoxycarbonylhydrazine the intermediate 2-[1-(-ethoxycarbonyl)hydrazino]ethylidene-1,3-cyclohexanediones were also isolated. From the potassium salt of 2-formyldimedone and 2-carboxyphenylhydrazine hydrochloride, 2-(2-carboxyphenyl)hydrazinomethylene-5,5-dimethyl-1,3-cyclohexanedione was obtained, the cyclization of which in ethanol in the presence of HCl led to 1-(2-carboxyphenyl)- and 1-(2-ethoxycarbonylphenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindazole.     

Application of Electrochemical Detection for the Quantitation of 1, 4-Dihydroxy-5, 8-Bis-[2-(2-Hydroxyethyl) Aminoethylamino]-9,10-Anthracenedione Following Liquid Chromatography

Abstract

Electrochemical monitoring of 1, 4-dihydroxy-5, 8-bis-[2-(2-hydroxyethy1) aminoethy amino]-9, 10-anthracenedione was employed for the quantitation of this cancer chemotherapy drug following high performance liquid chromatography. Detection was performed by oxidation of the compound at a glassy carbon electrode at +0.80 V vs. SCE. A rapid and convenient sample treatment procedure was developed which is suitable for determination involving physiological samples. A detection limit of 2 ng injected was obtained for urine samples.     

DIASTEREOSELECTIVE SYNTHESIS AND STEREOCHEMISTRY OF (Z)-1-[3-ARYL-2-(PHENYLSULFANYL)-2-OXIRANYL]-1-ETHANONES

Diastereoselective synthesis of a series of (Z)-1-[3-aryl-2-(phenylsulfanyl)-2-oxiranyl]-1-ethanones was effected from the reaction of (Z)-4-aryl-3-(phenylsulfanyl)-3-buten-2-ones with alkaline hydrogen peroxide in tetrahydrofuran. The stereochemistry of the oxiranes has been deduced from two-dimensional NOESY spectrum.     

Synthesis of （S）-2-（3-Arylacrylamido）-3-{4-[2-（5-methyl-2-phenyloxazol-4-yl）ethoxy]phenyl}propanoic Acids

The synthesis of （S）-2-（3-arylacrylamido）-3-{4-[2-（5-methyl-2-phenyloxazol-4-yl）etho- xy]phenyl}propanoic acids is described. Their structures were confirmed by ^1H-NMR.